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Abstract

Cellular Trafficking of Single and Multiple Vectors

Publication N° ___________

Silvia Ferrati, Ph.D.

Supervisory Professor: Mauro Ferrari.Ph.D.

Nanomedicine is an innovative field of science which has recently generated
many drug delivery platforms with exciting results. The great potential of these
strategies rely on the unique characteristics of the devices at the nano-scale in terms of
long time circulation in the blood stream, selective accumulation at the lesions sites,
increased solubility in aqueous solutions, etc.
Herein we report on a new drug delivery system known as a multistage system
which is comprised of non-spherical, mesoporous silicon particles loaded with second
stage nanoparticles. The rationally designed particle shape, the possibility to modulate
the surface properties and the degree of porosity allow these carriers to be optimized for
vascular targeting and to overcome the numerous biological barriers found in drug
delivery.
In this study we investigated the intra and inter cellular trafficking of the
multistage system in endothelial cells bringing evidence of its bio-compatibility as well
vii

as its ability to perform multiple intra and inter cellular tasks. Once internalized in cells,
the multi-particle construct is able to dissociate, localizing in different subcellular
compartments which can be targeted for exocytosis. In particular the second stage
nanoparticles were found to be secreted in microvesicles which can act as mediators of
transfer of particles across the endothelium and between different endothelial and
cancer cells.
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1 Background
1.1 Nanomedicine
When we talk about nanotechnology we refer to engineered particles or devices
that have at least one dimension between 1 to 100 nanometers (nm), but in a broader
classification we can extend the dimensions to 1000 nm 1. The underlying rationale for
this area of study is that at the nano-level particles or devices gain functional and
chemical-physical properties that are not found in the equivalent bulk materials.
Nanotechnology has wide applications ranging from biosensors, microchips, molecular
switches, etc. The application of this new field of science to medicine for treatment,
diagnosis and monitoring of disease has been recently referred by the National Institute
of Health in the USA as ‘nanomedicine’.
Since cancer is a leading cause of mortality all around the world, there is an
acute interest in developing new nanosystems to help find a cure for this malignancy 2.
A vast area of research is dedicated to developing new nano-delivery systems for preapproved drugs, especially chemotherapeutic agents

2a, 3

. Nanotechnology applied to

medicine has strong potential in helping to achieve the goal of delivering drugs to the
site of lesion, at the right time in a controlled fashion and at an effective therapeutic
concentration

2c, 4

. Ideally, these systems will permit a more specific accumulation of

the drug at the lesion, therefore increasing its efficacy and reducing side effects. In
particular, nanoparticles attract large amount of interest given their characteristic size
and the possibility to conjugate them with targeting ligands

5

(peptides, antibodies,

aptamers etc.) which selectively recognize cancer cells or tumor microenvironment such
1

as vasculature 6 or stroma 7. For instance folate, 8 peptides such as RGD 9 and antibodies
like anti-HER have been employed to target nanoparticles to the tumor site.
Most of the current chemotherapeutic agents are small molecules with a broad
pharmaco-kinetics which also causes them to interact with healthy tissues causing side
effects such as alopecia, nausea and bone marrow damage. In addition, these drugs are
easily excreted by the body and, therefore, high-concentration injections are required to
assure the therapeutic efficacy dosage, further increasing the toxicity. Most
chemotherapeutics are also hydrophobic molecules and are currently administered
solubilized in solvents that are toxic, such as cremophor EL.
In conventional nano-micro drug carriers, the therapeutic agent is encapsulated
or attached to particles which facilitates the solubility of the drug in aqueous solvents
and protects the drugs from enzymatic degradation, improving its stability. Moreover,
the encapsulation in particles combined with the targeting agents, facilitates cellular
uptake enhancing drug accumulation at the target site.
Many types of nanoparticles for drug delivery, imaging and diagnostics have
been developed in the past two decades, in particular, liposomes, polymeric
nanoparticles, micelles, Qdots, dendrimers, gold, super-paramagnetic iron oxide, silica
and silicon particles. Doxil and Abraxane are two well-known FDA-approved
chemotherapeutic nano-formulations already available on the market. Doxil is the
liposomal formulation of doxorubicin used for many types of cancers such as leukemia,
breast, lung and ovarian

10

. Abraxane is instead a water soluble formulation of

paclitaxel complexed with albumin nanoparticles which avoid the use of the toxic
solvent Cremofor

11

. Nanomedicine has also improved the delivery of genes

12

and

2

siRNA

13 14

offering an alternative to viral vectors. Nanoparticles conjugated to

transcription activated proteins (TAT) are rapidly and efficiently delivered to the
perinuclear localization in cells improving gene expression. In 2008 a phase I clinical
trial was conducted to study intravenously injected polymeric targeted nanoparticles
containing siRNA on patients affected by solid tumors15. The trials showed a significant
down-regulation of the specific gene of interest. Inorganic nanopaticles such as Qdots 16
and superparamagnetic iron oxide

17

(SPIOs) have instead been extensively studied as

imaging contrast agents. Qdots present several appealing characteristics for imaging
such as the ability to tune their fluorescent emission, a broad absorption range, a high
quantum yield and almost negligible photobleaching. On the downside their application
in vivo is limited by their toxicity 16 which makes optimized coatings necessary. Superparamagnetic iron oxide nanoparticles (SPIOs) on the contrary are made of
biodegradable iron and their surface can be coated with various polymers that allow
further conjugation of targeting molecules

18

. SPIOs are currently available in various

sizes and are used as contrast agents for magnetic resonance imaging (MRI) 19.

1.2 Biological Barriers
Both drugs and particles have to bypass multiple biological barriers before
reaching the target site 20. Among these barriers there are: sequestration by the reticuloendothelial system (RES), transport across vascular endothelium or gastrointestinal
epithelium, diffusion in the stroma and crossing of cell and subcellular organelle
membranes 21. As a result, only a minimal percentage of the drug reaches the lesion site
while the largest percentage accumulates in healthy organs, causing side effects.
3

These processes involve mass transport at multiple levels and in order to
understand the mechanisms that govern transport across these biobarriers and develop
more effective therapeutics it is necessary to bridge different scientific fields such as
biology, chemistry, physics and mathematics. In this regard nanomedicine, which is per
se a multi-disciplinary field, has brought an important contribution to the field of drug
delivery, developing carriers that, given to their small dimensions and unique surface
properties, have been able to reduce macrophage uptake and increase drug accumulation
at the tumor site. However, a deeper understanding of the ‘oncophysics’ is necessary to
develop more refined carriers and devices in order to successfully overcome these
biological barriers and fight cancer.
1.2.1 Endothelial Barrier

In order to reach the tissue level the injected drug/carriers have to leave blood
circulation and cross the endothelial barrier. The endothelial cells lining the blood
vessels constitute a size-selective semipermeable barrier that tightly controls the
diffusion of molecules from the blood to the interstitial space 22. Two major mechanism
of transport across the endothelial barrier have been identified: a paracellular pathway
across the cell junctions and a trancellular pathway through the cells.
The junctions between endothelial cells are mostly constituted by (VE)-cadherin
bound to catenins, an interaction that is crucial for the regulation of permeability 23. The
determination of molecules that can passively cross the blood vessel walls depends on
the organ and type of endothelium. The brain, for instance, presents virtually no
fenestrations while the remaining peripheral endothelium (capillaries) presents a cut off
of 6nm which allow small molecules to pass through the junctions between cells

24

.

4

Less continuous capillaries are also found in the kidney and liver with openings that can
reach 40-50nm 25. In the presence of inflammation or disease, like cancer 26, mediators
such as VEGF disrupt intracellular-junction organization, causing larger fenestrations
up to 2 µm, which make tumor blood vessels more permeable than regular organs. In
addition, tumors present a defective lymphatic system which contributes to the
enhanced permeability and retention (EPR) effect responsible for the increased
accumulation of macromolecules and fluids in the tumor region 27. Many drug delivery
systems, such as liposomes, exploit this unique pathophysiology of the cancer
vasculature to passively target particles of 100-150nm to the tumor site 27b, 28.
The transcellular pathway is mostly exploited by macromolecules larger than
3nm

25

. This mechanism, also known as receptor mediated transcytosis or carrier

mediated transport, involves the interaction of the cargo with transporters or receptors
expressed on the endothelium surface

22a

. Caveola, which is a membrane protein

expressed in 70% of the capillaries, is the major vesicular transporter in endothelial
cells. Caveola’s interaction with the cargo activates a mechanism of endocytosis with
membrane invagination of 50-100nm in size (caveolae) which pinch off creating
vesicles that traffic across the endothelial barrier, transporting the cargo. The study of
these types of interactions can provide ways to exploit these receptors and selectively
transport carriers and drugs across the endothelium

29

. Thus a new generation of

nanoparticles involves the functionalization of the carriers with moieties that improve
these specific interactions which increase accumulation at the target site. A good
example is Abraxane, in which the interaction of albumin with the gp60 endothelial cell
membrane protein was exploited to facilitate the transport of the therapeutic agents to

5

the tumor site

11

. Along the same lines, recently cRGD conjugation on doxorubicin

polymeric micelle has been shown to improve uptake by tumor endothelial cells
overexpressing ανβ3 integrins 30.
1.2.2 Stromal Barrier

Once extravasated from the blood stream, the carriers encounter the stroma
which constitutes an additional barrier to the penetration of the particles inside the
tissue

31

. Multiple factors affect this transport-step, in particular the degree of

vascularization of the organ, the extracellular matrix composition

32

, the presence of

inflammatory cells and the cell density 32-33. All these factors affect the tortuosity of the
path that the carriers have to perform to reach the target cells

31

. Moreover the stroma

not only reduces the diffusion of the therapy in the tissue and therefore its efficacy, but
because of the complex network of interactions between cancer cells and the tumor
environment, promotes tumor growth providing a permissive environment in terms of
nutrients, soluble factors, differentiation stimuli and fluid exchange.
The critical importance of these interactions was first proposed by Paget in
1889, when he suggested the ‘soil and seed’ theory 34. He hypothesized that the tumor
cells are like seeds that prefer to grow in hospitable soil. Now this idea is well
recognized and evidence of the stroma’s influence on angiogenesis, tumor growth,
invasion and metastasis have been reported. Each tumor type presents, however, a
characteristic stroma which can offer specific targets for therapies and potential markers
for disease prognosis. For instance, a high level of tumor-associated macrophages has
been correlated with poor prognosis for glioblastoma and breast cancers

35

, or the

extensive fibrosis in pancreatic cancer has been associated with the highly malignant

6

phenotype of the disease
pathway

37

36

. Anti-angiogenic therapies developed to block VEGF

, such as Avastin, fall into the category of therapies that target the tumor

environment and have shown good results. Another example is anti-TGF agents that
target pancreatic stroma in order to reduce the fibrosis and improve chemotherapy
efficacy 38.
1.2.3 Cellular Barrier

Many drugs elicit their efficacy once internalized in cells, acting on specific
intracellular organelles. Therefore, once the carriers reach the target cells, they will
encounter the cellular membrane as the next barrier. There are several mechanisms by
which a particle can be taken up by a cell, such as endocytosis, phagocytosis and
clathrin – dependent or clathrin – independent endocytosis.
Different characteristics of the carriers such as size, charge, shape and material
can dictate which pathway will be preferred and this will influence the final localization
of the carrier inside the cell and its potential toxicity. Understanding how these factors
influence the uptake and the intracellular trafficking of nanoparticles is helpful in order
to rationally design carriers. Particles smaller than 500 nm can be internalized by cells
through endocytosis

39

. The presence of specific ligands on the particles can further

target them through this pathway triggering receptor mediated endocytosis. In both
cases the cell membrane invaginates, creating vesicles (called cavaeolae) presenting a
size up to 500nm, which will encapsulate the particle or macromolecule, transporting
them inside the cell

40

. Particles bigger than 1µm are instead internalized by

phagocytosis which requires the elongation of the cellular membrane (pseudopodia) in
order to reach and engulf the particles

39

. Clathrin-mediated endocytosis also involves

7

the interaction of the cargo with specific membrane adapter proteins which trigger the
invagination and formation of clathrin-positive vesicles which mediate the particle
transport inside the cells

40

. For all the above pathways, once the vesicles are formed

and internalized, they fuse with late endosomes and subsequently with lysosomes as
part of their traffic toward perinuclear localization

41

. Clathrin-independent traffic

instead avoids this fusion.
Not only the size, but also the particle geometry can influence the mechanism
and rate of uptake. A systematic study conducted with macrophages correlated particles
size and shape with three potential up-take outcomes: successful phagocitosis,
attempted phagocytosis and unsuccessful phagocytosis

42

. The initiation of

internalization was driven by Ω, defined as the angle between the particle and the cell
membrane (correlated to the shape), but the completion of the process was shown to be
regulated by the volume of the particle. Moreover, since phagocytosis requires a
massive energy-consuming actin rearrangement with the formation of pseudopodia that
surround the particle following its geometry, particles whose geometry requires less
expansion of actin are more easily internalized. Mathematical models, integrating
particle-physico-chemical characteristics with biological parameters such as vascular
transport and margination have also been developed in order to predict the degree and
rate of particle uptake 43. Using these models, maps predicting the propensity of a given
carrier to adhere and be internalized by cells were developed.
Targeting moieties based on receptors or antigens overexpressed on diseased
cells or associated vasculature can also be used to direct the internalization through
receptor-mediated endocytosis

9b, 39

. Among the several methods available to find

8

signature markers, there is the in vivo phage display44, which has been used to identify
various tumor endothelial cell markers such as ανβ3 and ανβ5 integrins, CRKL,
GRP78, etc. Other targets such as the folate receptor 8, LHRH receptor 45 and PSMA 46
47

are instead expressed on tumor cells. Liposomes conjugated to folic acid have been

shown to be internalized by tumor cells faster through endocytosis compared to naked
liposomes, proving increased up-take specificity. Many folate-based carriers have been
recently developed and are currently undergoing testing in clinical trial. LHRH peptide
has been instead used to target campothcin to ovarian, breast and prostate tumors

48

.

Along the same line, a PSMA-targeting aptamer has been used to target PLGA-PEG
nanoparticles- containing cis-platinum to prostate cancer cells 49.

1.3 Secretion of Nanoparticles
Even if nanoparticles have shown great promise as drug carriers there are still
several fundamental problems that have to be understood and solved in order to refine
their use. Intracellular trafficking of micro and nanoparticles has been extensively
studied over the past decades. Particular interest has been spent in characterizing the
endocytosis and intracellular localization of the particles, but less focus has been given
towards investigating the long term retention of the particles in cells and their potential
secretion into the surrounding area.
Nanoparticles commonly enter into cells through endocytosis or phagocytosis,
resulting in their encapsulation in vesicles (early endosomes). These vesicles can then
mature into late endosomes, also called multivesicular bodies, and subsequently fuse
with either lysosomes or autophagosomes, in a complex pathway which creates various
9

types of intracellular vesicles: amphisomes, autolysosomes and lysosomes

50

.

Hypothetically, at any point, the pathway vesicles can be recycled to the cellular
membrane and released outside. Depending on the size and morphology, the secreted
vesicles are classified as: exosomes 51, less than 100nm in size, released by a wide range
of mammalian cells such as the cells of the immune system; microvesicles

52

, 100nm-

1µm, released by stimulated cells; and apoptotic bodies, larger than 1µm, released at the
end of cellular apoptosis. A few studies have reported the exocytosis of nanoparticles
such as PLGA53 and iron oxide particles54 and single walled nanotubes55, opening a
new, interesting field of research. The process is dynamic and it is hard to precisely
quantify the rate of endocytosis and exocytosis at the same time. Through microscopy
and single particle tracking Jin et al. has shown that the rate of exocytosis closely
matches the rate of the internalization of particles55. In the context of endothelial cells,
the exocytosis of PLGA particles in human vascular smooth muscle cells has been
reported 53, showing that the process depends on the presence of serum in the medium.
This suggests the involvement of opsonization in directing the internalized
nanoparticles through the exocytic pathway. However, the mechanism by which these
particles are released and the extent of this phenomenon across different cell lines is still
not clear.
Gauze

54c

et al. have shown that iron oxide nanoparticles can be released in

micro-biovesicles by macrophages, which are known to be able to shed their membrane
in physiological and pathological conditions such as stress, apoptosis or upon
activation, creating bio-vesicles which are released into the surrounding area. Similar
evidence was found by Wilhelm et al.

56

which identified biovesicles containing SPIOs

10

released by eukaryotic cells. The nature of these nanoparticle-loaded vesicles, however,
has not been investigated.
Many questions are therefore still unsolved and the impact of exocytosis and
inter-cellular transfer of nanoparticles on their biodistribution, therapeutic efficacy and
imaging characteristics.

1.4 The Multistage System
1.4.1 Strategy

Drug delivery carriers can be classified into 3 major classes: first generation
carriers are naked particles, developed about a decade ago, that passively target tumor
through EPR effect. Second generation particles added a level of complexity
introducing surface decoration such as targeting moieties, environment-triggered
activation, etc.; the third generation of carriers, instead, is composed of multiple nanoelements able to perform specific tasks in order to sequentially negotiate the biological
barriers that they will encounter during their journey from the site of injection to the
target lesion. Our multistage system (MSV) is an example of this class of carriers.
Our strategy is comprised of i.v. injectable stage 1 hemispherical nano-porous
silicon micro particles (S1MPs) loaded with stage 2 nano-particles (S2NPs) 57. S1MPs
have been rationally designed through a mathematical model in order to optimize the
three major processes that occur during the travel of the carrier in the blood stream:
margination on blood vessels walls, adhesion on the endothelial cells and control of the
internalization in cells

57-58

. Non spherical particles were shown to be the best

candidates as carriers since they drift better toward the vessel walls increasing the
11

probability of interacting with it. The mathematical model was confirmed with in vitro
experiments employing a parallel flow chamber and in vivo experiments in which
particles presenting different shapes were injected into animals bearing breast cancer;
these in vivo experiments showed hemispherical particles accumulated in the tumor in
greater numbers 59.
Once docked to the vasculature of the lesion site, the S1MPs release their cargo
which extravasates from the vasculature to reach the target. The schematic in Figure 1
summarizes the principle of our system. Porous silicon (pSi), was chosen as the
material, since it is FDA approved and it is compatible with biological systems given
the byproduct of its degradation is silic acid, a biologically harmless chemical.
Moreover the size, shape and porosity of the material can be tightly controlled through
semiconductor fabrication techniques therefore giving precise control over the final
design

60

. In addition, the versatility of silicon chemistry allows the conjugation of the

particles’ surface with active targeting moieties, polymers such as poly(ethylene glycol)
(PEG), etc. to increase circulation time and tumor accumulation 61.
The S2NPs loaded into the pores of the silicon carriers can be any type of
nanoparticles from liposomes to micelle or polymeric particles which can also be loaded
with therapeutic drugs, contrast agents or combinations of the two generating a vast
selection of options. Metal nanoparticles such as SPIOs or gold can also be loaded and
can function as contrast agents as well as thermo-ablation agents once the heat
production is triggered by radio frequency or near infrared energy. This makes the
system very versatile in terms of applications and possible payloads. Figure 2
recapitulates the possible types and combinations of S1MPs and S2NPs as well as
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surface functionalizations and particle parameters to highlight this fundamental
characteristic.

Figure 1 Schematic summarizing the principle of our multi
multi-stage
stage system. The S1MP
porous silicon carriers are loaded with nanoparticles (S2NP) and then i.v. injected.
injected After
docking on the lesion vasculature the carriers release the S2NPs which cross the
vasculature and reach the tumor cells (Tasciotti
Tasciotti et. al. Nature Nanotechnology, 2008,
Courtesy of Nature Publishing Group
Group).
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1.4.2 S1MP Fabrication

The fabrication of the S1MPs is comprised of a combination of photolithographic,
reactive ion-etch, electro-chemical etch and particle release steps on heavily doped 100
mm silicon wafers (p++, (100), <0.005 Ωcm). The 3.2 µm hemispherical particles are
made by first depositing a sacrificial layer of silicon-rich silicon nitride on the wafer.
This is followed by a photolithography process using AZ5209 photoresist to imprint a
pattern of 2 µm diameter circles using a chrome-plated mask. Then a series of reactive
ion etches are applied to remove parts of the sacrificial silicon-nitride layer, exposing
the surface of the wafer with 2µm holes. The photolithographic resist is then removed
using a ‘pirahna’ solution after which the wafer undergoes an electro-chemical etch
(EC-etch) to create the porous layers of the particles. The pore size, degree of porosity
and thickness of the particles can be tuned during the EC-etch step by varying the
electric current, chemical-solution concentrations and etching time. Based on the
knowledge in fabrication protocols developed in our laboratories, and by modifying
various parts of the standard process, we can produce particles with dimension ranging
from 500 nm to 3.2 µm, with pores from 5 to 80+ nm, in both hemipherical and
discoidal shapes. The high degree of porosity allows the loading of a large amount of
S2NPs and, at the same time, control of their release profile based on particle
degradation.
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Figure 2 Versatility of our MSV in terms of size, shape, degree of porosity, surface
properties (negatively and positively charge groups, PEG or other polymers,
functionalization with antibodies, peptides, aptamers and fluorescent probes) and
possible payloads (liposomes, micelles, inorganic/metallic nanoparticles, carbon
nanotubes) (Biana et al. Accounts of chemical research, 2011, Courtesy of ACS
Publication).
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2 Methods
2.1 Cell Culture
Human microvascular endothelial cells (HMVECs) were received as a gift from Dr.
Rong Shao (University of Massachusetts) and grown in EBM® medium, (CC-4133®,
Lonza, Walkersville) while Human Umbilical Vein Endothelial Cells (HUVECS),
bought from Lonza, Walkersville, Inc, were cultured in EBM®-2 medium (CC-3124®
, Lonza, Walkersville).
Both cell lines were grown in monolayers 80% confluent in at 37C in 5% CO2. Cells
detachment was performed with 0.25% mg/ml trypsin solution (Clonetics).

2.2 Porous Silicon Particles and Surface Functionalization
Hemispherical silicon microparticles were manufactured by our group at the
Microelectronics Research Center at University of Texas at Austin using lithographic
techniques. Particles were produced in two sizes: 1.6±0.2 and 3.2±0.2 µm; with pores
size ranging of 26±0.2 µm, for hemispherical one, and 53±0.2 µm for discoidal one.
Particles were heated at 110ºC in piranha solution (1 volume H2O2 and 2 volumes of
H2SO4) for 2 hours to oxidize their surface and create a negative surface charge.
Washing steps with deionized (DI) water were used at the end of the oxidation process
before re-suspending the particles in isopropyl alcohol (IPA), where they are usually
stored till their use. 3-aminopropyl-triethoxysilane (APTES) was employed to create a
positive coating on the particles. The conjugation was conducted suspending the
particles in a solution of 0.5% (v/v) APTES in IPA for 2 hours at room temperature.
Both modifications were evaluated checking the particles surface charge by zeta
potential. In order to functionalize the particles with poly(ethylene glycol) (PEG),
APTES-modified particles were incubated for 1.5 hours with 10nM PEG-5000 (Laysan
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Bio Inc.) in acetonitrile and subsequently washed with DI water to remove the unconjugated PEG.

2.3 Scanning Electron Microscopy
4x104 cells were seeded on silicon chip supports (Ted Pella, inc, Redding, CA) in a 24
well plate. Upon confluence, cell were incubated for 15 min with 1.6 or 3.2 µm
oxidized particles (ratio 10:1 particles per cell) at 37 ºC in serum-free medium. Cells
were then washed with PBS, fixed with 2.5% glutardehyde (Sigma-Aldrich, Saint
Louis, MO) and washed again in PBS. Samples were then dehydrated incubating in
progressively more concentrated solutions of ethanol (30%, 50%, 70%, 90%, 95% and
100%) for 10 minutes each. As last step, cells were incubated 10 minutes with a
solution of 50% (v/v) ethanol-hexamethyldisilazane (Sigma, Saint Luis, MO) followed
by 5 minutes in 100% hexamethyldisilazane. Samples were dried overnight in a
dessicator. Silicon chips were mounted on SEM stubs (Ted Pella, Inc. Redding, CA)
with the help of conductive adhesive tape (12mm OD Pelco, Ted Pella, Inc. Redding,
CA), sputtered with a 10 nm film of gold by means of a Plasma Science CrC-150
Sputtering system (Torr International, Inc.) and then they were imaged with a FEI
Quanta 400 FEG-SEM (high vacuum conditions, 20kV, spot size 5).

2.4 Transmission Electron Microscopy
HMVECs were grown at a concentration of 1x106 cells/well in a 6 well plate and then
incubated 6 hours at 37 ºC with 1.6 and 3.2 µm hemispherical particles, either oxidized
or APTES modified. After the samples were washed with PBS, the fixation step was
performed with a solution of 2% paraphormaldehyde (Electron Microscopy Science,
Hatfield, PA) and 3% glutaraldehyde (Electron Microscopy Science, Hatfield, PA) in

17

0.001 M phosphate buffer saline (PBS), pH7.4. Samples were then washed, treated with
0.1% Millipore-filtered cacodylate buffered tannic acid and then stained with 1%
buffered osmium tetroxide for 30 min followed by 1% millipore-filtered uranyl acetate.
The samples were subsequently dehydrated in progressively more concentrated
solutions of ethanol (30%, 50%, 70%, 90%, 95% and 100%) and then infiltrated with
Epon resin. The resin-embedded samples were let polymerized in an oven at 60 ºC for 2
days. A Leica Ultracut microtome (Leica, Deerfield, IL) was employed to obtain
Ultrathin sections of the samples which were then stained with uranyl acetate and lead
citrate in a Leica EM Stainer. Images were acquired with a JEM 1010 transmission
electron microscope (JEOL, USA, Inc., Peabody, MA) with a voltage of 80 kV.
The same procedure was used to investigate the trafficking of the MSV and SPIOs in
endothelial cells. For the first experiment, HMVECs were grown in a 6-wells plate till
80% confluence, were then incubated with the assembled MSV system for 24 hours (5:1
particles/cell) and then processed for TEM. For the second experiment, HMVECs were
plated at a concentration of 1x106 cells/well in a 6 well plate and then incubated 6 hours
with PEI-SPIOs (7µg/ml). Cells were subsequently fixed and processed for TEM
imaging. The same protocol was also carried out with HMVECs, 4T1 and MCF7 cells,
after incubation overnight with microvesicles concentrated from the HMVEC’s
supernatants well as with the concentrated microvesicles pellet.

2.5 Confocal Microscopy
HUVECs were let adhere overnight on 1.5 mm glass coverslips and then they were
treated with 3.2 µm silicon particles (5:1 particles to cell ratio) for 2 hours at 37 ºC.
After being washed with PBS, cells were fixed with 4% paraphormaldehyde,
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permeabilized with a solution of 0.1% Triton X-100 and blocked with a solution of 1%
Bovine Serum Albumin (BSA) in PBS. Cells were then stained with 200 nM Alexa
Fluor 555-Phalloidin (Invitrogen, Carlsbad, CA). Coverslips were then mounted on a
confocal glass slide using Vectashield mounting media (Vector Laboratories,
Burlingame, CA). Images were acquired with a Leica DM6000 confocal microscope
with a 63x oil objective. Particles were visualized using auto-fluorescence exciting with
a 633 laser.
In order to characterize the mechanism exploited by our particles to traffic inside cells,
HMVECs were grown till 80% confluence on 1.5 mm glass cover slips and then they
were incubated with 3.2 µm silicon particles for 5 hours. The behavior of cell in regular
medium was compared to cells grown in medium containing 150 nM nocosazole
(Sigma, St. Luis, MO). Cells were processed for confocal following the standard
procedure of fixation, permeabilization and blocking as previously reported. FITClabeled anti-α-Tubulin monoclonal antibody (Abcam) at 1:200 dilutions was employed
to stain the cell microtubules. Nuclei were stained with DRAQ5 (Biostatus Ltd) at
1:1000 dilution. Coverslips were then as usual mounted on a confocal glass slide using
Prolong Gold as mounting media (Vector Laboratories, Burlingame, CA). Images were
acquired with a Leica DM6000 confocal microscope with a 63x oil objective. Particles
were visualized using bright field.
To confirm the particles co-localization with phagolysosomes we transfected a GFPNPC1 construct (kind gift of Dr. J. Suh at Rice University) into cells with the help of an
Amaxa Electroporator. 1x10 6 cells were trypinized, resuspended in 100 µl of Amaxa
HUVECs nucleofactor solution (Lonza, Walkersville, MD), combined with 5 µg of
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DNA and transfected with the appropriate electroporator programmed ramp. Cells were
then diluted in medium and immediately plated on a glass bottom dish. Upon reached
confluency, cells were incubated for 2 hours with 3 different variation of paricles: 3.2
µm 594-dylight (Pierce)-conjugated particles 3.2 µm and 1.6 µm APTES-modified
particles, then washed with PBS , fixed and imaged with an 1x81 Olimpus Microscope
equipped with a 40x objective.
In order to investigate SPIOs trafficking in endothelial cells, 5x104 HMVECs were
plated on an 8 well glass bottom confocal chamber slide (BD Falcon) and left to adhere
overnight. After cell membrane staining for 10 minutes at 37C with 594 wheat germ
agglutining (WGA) (Invitrogen), cells were incubated with 488-dylight (Pierce)
conjugated PEI-SPIOs (5µg/ml final concentration) overnight. The samples were then
fixed with a 4% paraphormaldehyde solution, mounted with prolong gold mounting
medium on confocal slides and imaged with a A1 Nikon confocal microscope.
For the staining of concentrated microvesicles, the pellet was instead fixed with 4%
paraphormaldehyde solution, washed once with a solution of 0.1% BSA in PBS and
then stained with Alexa Fluor 488-Lamp1 antibody, 1:50 dilution, (Santa Cruz
Biotchnology ) for 1 hour at room temperature. The pellet was then washed with PBS
and incubated overnight with 4T1 breast cancer cells, previously seeded in glass bottom
confocal chambers. 4T1 were then fixed with 4% paraphormaldehyde, mounted with
prolong gold and imaged with a confocal Nikon microscope. Reflectance was used to
visualize the iron oxide nanoparticles contained in the FITC-labelled vesicles.
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2.6 Live Microscopy
For the live cell imaging, HMVECs (25x103 per well) were grown on a 24 well-glass
bottom dish (Mat Tek corporation, Ashland MA). 3.2 µm or 1.6 µm APTES-modified
particles as well as 3 variations of spherical silica beads (1, 2.5 and 3 µm) were added to
the cells. The samples were visualized with a 1X81 Olimpus Micriscope equipped with
a humidified 37 ºC incubator with 5% CO2 , images of 5 focal planes were taken with a
20X at 5 minutes intervals for 19 hours. The more rapresentative shots are reported as
still images, while the the remaning pictures were projected and compiled into movies.
Particles tracking was permormed using Slide Book software, analyzing the x and y
coordinates of the particles over time. The mean square displacements (MSD) were
calculated with the following equation:
∆  

 

   



    

From which, through fittings, it was possible to calculate the rate of intracellular
trafficking. Calculations and fitting were performed with Excel.

2.7 Fluorescence Microscopy
For the quantitative analysis of the mitotic trafficking of microparticles, HMVECs were
grown in a petri dish and subsequently incubated with 488-dylight (Pierce)-conjugated
3.2 µm particles (10:1 particles/cell) overnight to ensure internalization. The population
of cells presenting the highest fluorescence and therefore the higher number of
particles/cell was selected with a Becton Dickinson FACS Diva Flow Cytometer and
Cell Sorter (BD Bioscience, San Jose, CA). The sorted cells were then plated in glass
bottom dish at 5 different concentrations, starting from 25000 cells and diluting 1:2 till
800 cells per well. Every 24 hour for 6 days, bright field and fluorescent images of the
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cells were acquired with a fluorescent microscope (Nikon TS 200) with a 20x objective.
The number of particles per cell was manually determined from the images.

2.8 Flow Cytometry
1.6 µm APTES-modified particles were conjugated to a pH sensitive dye (pH RhodoNHS Ester, Invitrogen, Carlsbad, CA), which becomes fluorescent in acidic pH. The
conjugation between the carboxyl group of the dye and the amino group of the APTESparticles was conducted in DMSO directly adding the dye solution to the particles
incubating for 2 hours at room temperature. Particles were then washed twice with
DMSO and twice with IPA to remove the un-bounded dye. Cells, plated on a 6 well
plate, were starved in serum-free medium for 40 minutes before adding the pH-Rhodoparticles at a 10:1 particles/ cells ratio. Plates were centrifuged at 1500 rpm to let the
particles settle down before incubation at 37 ºC for different amounts of time. Cells
were then trypsinized, fixed and analyzed with a Becton Dickinson FACS caliber and
Cell Quest software.

2.9 Enzyme-linked immunosorbent assay (Elisa)
HUVECs, seeded at 50000 cell/well in 24-well plate, were incubated with either 3.2 µm
APTES-modified particles or PEG-500 (5:1 particle/cell). 20 µg/mL zymosan was used
as positive control for cytokines up-regulation. 100 µl of the cell medium was collected
at different time points (1, 4, 24 hours) and stored at -80 ºC till analysis. The removed
medium was each time replaced with fresh medium. Interleukin-6 (IL-6) and
interleukin-8 (IL-8) were measured in the medium using the Human IL-6 and IL-8
ELISA Kits (Cell Science) following the manufacture protocol.
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2.10 Tube Assay
HMVECs were pre-labeled by incubating them for 15 minutes at 37º C with orange cell
tracker (Invitrogen, Carlsbad, CA). 4 x 104 labeled HMVECs were then seeded on 80 µl
of matrigel (Geltrex, Gibco, Grand Island, NY) in a glass bottom confocal chamber slide
(BD Falcon, San Jose, CA) in the presence or absence of 488-Alexa Fluor (Piercelabeled 3.2 µm S1MPs and let adhere overnight. The slides were then imaged with a A1
Nikon confocal microscope equipped with a 20x objective.

2.11 Zeta Potential and Fourier Transform Infrared Spectroscopy (FTIR)
The surface charges of 15 nm amino-polyethylene glycol (PEG) polymer coated SPIOs
nanoparticles (NH2-PEG SPIOs) (Ocean nanotech, Springdale, Arkansas) and oxidized
silicon particles were tested with a Zeta Potential Analyzer (Zeta PALS). Three
measurements were taken in both PBS (pH7) and borate buffer (pH5) and the final
value reported was the average.
The qualitative analysis of the NH2-PEG SPIOs surface coating was performed with
FTIR and compared to carboxylated SPIOs. Dried samples were applied directly to the
on the diamond surface of a SMART ATR attachment on a Nicolet 6600 FTIR spectrophotometer. Data were collected with a resolution of 4cm-1 and as an average of 16
readings. The peaks analysis was performed with Omnic Peak Identification software.

2.12 Porous Silicon Particles Loading
In order to assemble the multistage system, 1x10 7 3.2 µm S1MPs were dried from IPA
overnight and then incubated with 100 µg of 15nm SPIOs in borate buffer (stock
solution 1mg/ml) for 30 min at room temperature. Samples were then washed twice
with DI water to remove the un-loaded SPIOs. Porous silicon particles were recollected
each time by centrifugation at 2000 rpm (Beckman Coulter Allegra X-22 Centrifuge
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equipped with a 296/06 rotor). To evaluate the loading efficiency, we measured the
content of iron in the washing solutions as well as silicon carriers pellet by means of
inductively coupled plasma optical emission spectroscopy (ICP-OES) with a Varian
Vista AX (power set at 1kW, plasma flow set at 15L/min, auxiliary flow of 1.5L/min
and a nebulizer flow of 0.75L/min, 5 replicates).

2.13 Inductively Coupled Plasma Optical Emission Spectroscopy
In order to quantify the concentration of iron in the supernatant over time, HMVECs
were seeded in a 6-wells plate, once reached 80% confluence, they were incubated with
3x106 loaded MSVs per well. Free SPIOs (5µg) were used as comparison. After 12
hours cells were washed to remove particles not yet up taken and fresh medium was
added to obtain the actual initial iron concentration. The amount of iron present in the
medium at this time point was subtracted by the initial amount of iron added.
Conditional medium was then collected over time at 1, 3, 5 and 7 days. Cells were split
after 3 days and the media from the two wells were summed at the end before analyzing
iron content. Collected samples were concentrated by centrifugation at 4200 rpm for 30
minutes and the pellets were then dissolved incubating with 10µl of 10-12 M
hydrochloric acid, for 2 hours at 60 ºC shacking at 1300rpm. The samples were then
brought to the same volumes (5ml) with spectrosol solution (CFA-C, Spectrosol Inc.) at
pH8.5. Iron standards were prepared at concentrations of 10, 25, 50, 100, 250 and 1000
mg/L. Spectrosol solution was used as blank while a solution of iron at 125mg/L was
used as the quality control standard.
50µl of an yttrium solution (stock solution 100mg/ml) were added to each samples and
standard as internal reference. Iron content was quantified with a Varian Vista AX ICP-
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OES (power set at 1kW, plasma flow set at 15L/min, auxiliary flow of 1.5L/min and a
nebulizer flow of 0.75L/min, 5 replicates).

2.14 MTT Cell Proliferation Assay
HMVECs were seeded into 96-well plates (5000cell/well in 200 µl medium) and left to
adhere overnight. Cells were then incubated with 15nm Polyetilenamine (PEI)-coated
SPIOs (Ocean Nanotech) at a concentration of 2µg/ml for 24 hours. The medium was
then replaced with fresh medium and cell proliferation was checked at 24, 48,36 and 72
hours

adding

200ul/well

solution

of

3-(4,5-dimethylthiazol-2-yl)-2,5-

dipheniltetrazolium bromide (MTT reagent, Sigma) at 0.5mg/ml. Cells were incubated
with MTT reagent for 2 hours and then the solution was replaced with 200 µl dimethyl
sulfoxide (DMSO). After 15 minutes incubation at room temperature absorbance was
measured at 570nm with a Synergy H4 plate reader (BioTek).

2.15 Concentration and Magnetic Purification of Biovesicles
HMVECs cells were cultured in a T150 flask and once reached 80% confluence they
were incubated with 2µg/ml PEI-SPIOs for 12 hours. The medium was then replaced
with fresh medium to remove non uptaken particles. Conditional medium from the cells
was then collected at day 3 and concentrated by centrifugation (21000xg 5 minutes).
The brown pellet obtained was then re-suspended in PBS and further purified with
magnetic separation overnight employing a magnet cuvette holder (Ocean Nanotech).
The separated pellet, containing the SPIOs, was then processed for further
experimenting as follow.
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3 Results and Discussion
3.1 Intracellular Traffic of Porous Silicon Micron-Particles
3.1.1 S1MPs Uptake by Endothelial Cells and Micro-Tubules Mediated Transport

Like many particles carrying systems, our multistage system is i.v. injectable
and therefore it will have to interact with endothelial cells, in order to reach the lesion
site. Moreover, since the vasculature of many lesions, among which cancer, presents
unique characteristics in terms of structure 27b and markers 62, endothelial cells are often
the primary target for the drug delivery systems

6, 63

. Therefore the study of the

interaction of our system with endothelial cells is of fundamental interest to understand
the mechanism of uptake and release of particles in cells as well as their
biocompatibility.
We employed microscopy techniques and in vitro assays in order to characterize
the mechanism of uptake, intracellular localization of the carriers and impact of
particles presence on cellular morphology, viability and cell cycle. As a model for this
study we choose two endothelial cell lines: human microvascular cells (HMVEC) and
human umbilical endothelial cells (HUVEC). Size, shape and surface properties of the
particles can influence their interaction cells and therefore the impact of these
parameters on the mechanism of particle uptake was of particular interest for us.
Endothelial cells acted as non-professional macrophages internalizing S1MP particles
through a combination of phagocytosis and macro-pinocytosi. Both mechanisms relied
on an extensive actin rearrangement that led to an actin cup formation which
surrounded and engulfed the particles. The early steps in the internalization of particles
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were documented in a previous work with scanning electron microscopy (SEM)
micrographs64. The process looks similar for both 1.6 or 3.2 µm SIMPSs with cellular
pseudopodia elongating and reaching the particles within 15 minutes incubation with
HUVECs at 37ºC. The subcellular localization of S1MPs was investigated by
transmission electron microscopy (TEM) and confocal microscopy. 1.6 and 3.2 µm
silicon particles, positively and negatively charged, were employed for this experiment.
The surface modification of the particles was achieved by oxidation with piranha
solution and 3-amino-propyltriethoxysilane (APTES) conjugation, respectively.
HMVEC cells were incubated with particles for 6 hours and then fixed and prepared for
TEM. The micrographs show the internalized particles localized in vesicles
(phagosomes). The magnifications in Figure 3 clearly show the tight membrane
surrounding the particles, for both particles sizes (Same result were obtained for
oxidized particles, data not reported). Confocal images of HUVECs incubated for 60
minutes with oxidized S1MPs and subsequently stained for actin were also acquired.

Figure 3 TEM micrographs of APTES modified particles incubated with HMVECs for 6
hours. In the top two images the particles are 3.2 µm in size while in the bottom two they
are 1.6 µm in size. (Ferrati et al.’ Intracellular trafficking of silicon particles and logic27
embedded vectors’ Nanoscale 2010, Courtesy of RSCPublishing).

Subcellular details, such as organelles and nuclei, displayed in TEM images
appeared healthy. In addition the surface charge and size did not seem to influence the
compatibility of the particles to be internalized by endothelial cells or the characteristics
of the vesicular compartments that housed them.
Once formed inside the cell, the phagosomes fused with endosomes and later on with
lysosomes in a process of maturation that requires the transient association of several
different proteins on the vesicles membrane. EEA1 and Rab5 proteins play a role in the
early stage of maturation while Lamp1 and NPC1 are recruited in the later stages. These
motor proteins are necessary to traffic the phagosomes into the cells, docking them on
the microtubules. This mechanism promotes a centripetal movement of the vesicles
which brings them into the perinuclear area. In order to understand if our particles were
moving inside the cells, exploiting the same trafficking mechanism, we incubated 3.2
µm S1MP particles with HMVECs cells for 6 hours in the presence or absence of 150
nM Nocodazole, which disrupts microtubules, thus inhibiting this specific trafficking
mechanism. Cell nuclei were stained with DRAQ5 and the microtubules were stained
with a FITC-labeled α-tubulin antibody. To evaluate the particles distribution in the
cells with respect to the nuclei, cells were divided into quadrants presenting defined
distances from the nuclei and the number of particles per quadrants was evaluated
(Figure 4). The nocodazole-mediated disruption of microtubules reduced particles
ability to accumulate in the perinuclear area by 80%. This provided insight into the
intracellular mechanism of transport of the particles which resulted microtubules
mediated and not randomly diffusive.
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Figure 4 Confocal images of particles internalized with
regular HMVECs (top figure) or nocodazole-treated
HMVECs (bottom row). Cells were stained with a FITCα-Tubulin antibody for microtubules and DRAQ5 for
nuclei (Ferrati et al. ‘Intracellular trafficking of silicon
particles and logic-embedded vectors’ Nanoscale 2010,
Courtesy of RSCPublishing).
3.1.2 Maturation of Phagosomes Bearing S1MPs

A well-known property of mature phagosomes is their acidity. The pH of the
vesicles slowly decreases from 7 to 5 as phagosomes fuse with late endosomes and
lysosomes. To evaluate the integrity of the pathway and the long term fate of the
internalized particles we conjugate a pH sensitive dye (pH Rodo, Invitrogen) on the
surface of 3.2 µm silicon particles, which emits fluorescent light in acidic environments.
We then tested the pH-Rhodo particles measuring the increase in fluorescence of the
particles in solution presenting different pH levels. This confirmed an increase in
fluorescence, from 2.2 to 27, passing from pH 7 to pH 4. We then tested these particles
in HMVECs performing a time-course incubation experiment evaluating cell
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fluorescence a different time points. This showed an increase in the mean fluorescent
intensity of cells over time from an average of 5 at time zero, when the particles are still
on the cell surface, up to an average of 19 after 16 hours of incubation (Figure 5 A). We
observed a slightly decrease in intensity at 24 hours which may occur because of
particles degradation or cleavage of the dye from their surface.
Overall this data indicates that the vesicle traffic machinery is not negatively
affected by our particles and phagosomes containing S1MP are still able to mature and
accumulate in the perinuclear region moving along the microtubules. To confirm
particle co-localization with phagolysosomes we trasnfected HMVECs with a construct
presenting GFP fused with Nieman Pick C1 (NPC1) in order to specifically label the
lysosomes. Next we incubated the trasfected cells with Dylight 594-labelled 3.2 µm
particles and imaged with confocal microscopy. Figure 5B shows the acquired images
in separate and combined channels to highlight the GFP-NPC1 expression (the green
ring) in the membrane surrounding the internalized particles, which suggests the
localization of particles in lysosomes. Since the presence of the fluorophore on the
particles could theoretically influence the intrinsic traffic of the carrier, we also
performed the experiment with 1.6 and 3.2 µm unlabelled particles, obtaining similar
results (Figure 5C).
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Figure 5 A) Flow cytometry analysis of pH-Rhodo-conjugated particles incubated for
up to 24 hours with HMVECs. The cells mean fluorescence is reported over time. B)
and C) Confocal images of GFP-NPC1 transfected HMVECs incubated for 4 hours
with either dylight 594-conjugated silicon particles B) or un-labeled particle C). The
images are presented in merged and separated channels (Ferrati et al. ‘Intracellular
trafficking of silicon particles and logic-embedded vectors’ Nanoscale 2010, Courtesy
of RSCPublishing).

3.1.3 Intracellular Mobility and Trajectory of S1MPs

In order to further evaluate the effect of size, shape and charge on the
intracellualr traffic of the particles we evaluated and compared the trajectory,
directionality and rate of migration toward the perinulcear region of different
varaiations of carrriers employing real time confocal microscopy. In particular we
analyzed 1.6 and 3.2 µm hemispherical porous silicon particles, positively and
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negatively charged, as well as three sizes of spherical beads (1, 2.5 and 3 µm). Movies
compiled by assembling images taken every 5 minutes for 19 hours over 5 focal planes,
were used to manually track particles inside the cells, from the moment they interacted
with cell surface until they reached the perinuclear region (Figure 6 A). The twodimensional time- dipendent coordinates [  ,  ] of the particles were used to
calculate individual time-averaged mean square displacement (MSDs) employing the
following equation:
∆   

 

   



    

Where  is the 5 minutes time lag between image acquisition.
Once generated, the MSD curves were fitted with the equation: 

6



(fitting 1 Figure 6 B). In the specific case of k=1 the equation becomes Fick’s law,
which describes random, thermally driven diffusion. When   1 instead, the equation
describes the active transport where molecules or particles migrate toward a defined
direction. All of the MSD curves were fitted with the equation presenting   1 which
confirmed that the particles were moving inside the cells with an active transport that
we previously found to be microtubule mediated. Transport rate for active traffic can be
calculated using the following equation: ∆   
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(Fitting 2 Figure 6 B)

where the two terms describe respectively the random diffusion and the active
contribution with  the diffusion coefficient and  is the rate of intracellular trafficking.
We calculated the rate of perinuclear migration of multiple particle variations obtaining
a consistent average rate of 0.5 µm per minute for all samples (Anova test with P=0.005
was used to compare the populations). This result, reported in Figure 6 B in the box
charts, suggested that the rate of intracellular migration of the particle-loaded
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phagosomes is not influenced,
luenced, at least in the used range, by the particles size (1.6 and
3.2 µm)
m) the shape (hemispherical and spherical) and the charge (negative and positive).

Figure 6 Intracellularr rate of migration: effect of size and shape. A) Example
of manual tracking of a single particles from the moment it start interacting
with the cellular membrane till the point it reaches the perinuclear localization.
Images acquired each 5 min with confocal microscope (scale bar 10
10µm).
m). B)
Top graph represents an example of MDS curve fittings
fittings.. Bottom graphs report
as box charts the rates of perinuclear migration of different types of micromicro
particles: oxidized (ox) and APTES – modified hemispherical silicon particles
(1.6 and 3.2 µm)
m) and spherical silica beads in three sizes (1, 2.5 and 3 µm)
(Ferrati
Ferrati et al. ‘Intracellular trafficking of silicon particles and logiclogic
embedded vectors’ Nanoscale 2010, Courtesy of RSCPublishing).
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3.1.4 Mitotic Trafficking

For biomedical application it is important to understand the impact of particles on
cellular events such as the cell cycle. The effect of the particles presence as well as their
redistribution during proliferation could potentially introduce disparities and challenges
in imaging or treatment of the cells. We therefore investigated the ability of cells
containing particles to undergo mitosis by means of real time confocal microscopy, with
particular interest on the fate of the particles. Taking images in five focal planes every 5
minutes for 24 hours, we
were able to capture the
all sequence of events
during the mitotic process
of

HMVECs-bearing

particles. The mechanism
of

endosomes

traffic

during mitosis involves
microtubules, with a

•

Figure 7 Real-time confocal imaging of HMVECs
containing 1.6 µm particles undergoing mitosis. The
white arrows highlight the initial cell and then the
two daughter cells containing equal amounts of
microparticles (Ferrati* and Serda* et al. ‘Mitotic
trafficking of silicon microparticles’ Nanoscale,
2009, Courtesy of RSCPublishing). *shared first
authorship.

centripetal movement of
vesicles

toward

the

central region in the first
part of the process, and a
polarized

partitioning

along

intercellular

the

bridges toward the end of the process. Mitotic traffic of endosomes-containing particles
appear to follow the same mechanism, with the particles accumulating in the central
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region after approximately 30 minutes from the beginning of the process (Figure 7, top
right) and then migrating in the two daughter cells a later time points. During this highly
ordered process organelles, such as endosomes, are therefore equally divided between
two daughter cells. The integrity of the process was found to be unaffected by the
presence. Figures 7 and 8 show indeed a time-lapse sequence of images of a cell,
containing respectively 1.6 or 3.2 µm particles before the mitotic event, and equally
partitioning the particles between the two daughter cells during the cellular division.

Figure 8 Real-time confocal imaging of HMVECs containing 3.2 µm particles
undergoing mitosis. The white arrows highlight the initial cell and then the two
daughter cells containing equal amounts of microparticles (Ferrati* and Serda* et al.
‘Mitotic trafficking of silicon microparticles’ Nanoscale, 2009, Courtesy of
RSCPublishing) *shared first authorship.

This is consistent with the fact that each S1MP is encapsulated in phagosomes,
as we have shown in TEM micrographs, therefore each particle represents an endosome
and follows the same fate of the single vesicles during the process. This study
confirmed that particles are not compromising cellular function, resulting in compatible
and safe use for in vivo study. Partitioning of S1MPs showed persistence over longer
time points as it was monitored for 6 days by means of fluorescent microscopy.
HMVECs were incubated with 3.2 µm fluorescently labeled particles and then sorted
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with FACS to assure a homogeneous population of particles-containing cells. Number
of particles per cell was manually counted each day using the bright field images to
define cell boundaries and fluorescent images to evaluate particle content. Two
representative images of days 2 and 6 are reported in Figure 9 A , the particles counts
over time are reported as a Box and Whisker Chart (Figure 9 B) where the statistical
boxes summarize the 25th, 75th,50th percentiles and the average number of particles in
the cells is written on top of each box. Significant changes in particles content, based on
ANOVA test with P=0.005, were marked with an asterisk and well were correlated with
the 48 hours doubling time of HMVECs. Indeed each 48 hours the average number of
particles per cell decreases by half, confirming particle partitioning during mitotic
events over time, for both 1.6 and 3.2 µm particles.
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Figure 9 Quantitative analysis of the number of particles per cell during proliferation.
FITC-labeled particles were incubated with HMVECs and then a homogenous
population of cells with equal number of internalized particles was sorted at FACS
based on fluorescence. A) Representative fluorescent images of HMVECs- containing
particles at day 2 and 6. B) The number of particles per cells at different time points is
represented through statistical box charts. The 25th, 75th (box margins) and 50th (middle
line) percentiles and the average number of particle per cell per day (number on top of
the box) are reported. Statistically different amounts are marked with a star (Ferrati*
and Serda* et al. ‘Mitotic trafficking of silicon microparticles’ Nanoscale, 2009,
Courtesy of RSCPublishing) *shared first authorship.

3.1.5 Direct Cell-to-Cell transfer of Silicon Microparticles.

After having analyzed the impact of microparticles on endothelial cell
proliferation and mitosis, we investigated the retention of particles within the cells and
their possible intercellular transport. Real time confocal microscopy was employed to
monitor HMVEC cells incubated with 3.2 µm oxidized silicon particles overnight.
Direct cell-to-cell transfer was observed as reported in the time-lapse sequence of
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pseudo colored (Figure 10A) and unaltered confocal images (Figure 10B). In the
sequence of images a cell (colored in blue, which we called the ‘donor cell’) containing
one particle, transferr it to the neighbor cell (red cell, which we called the ‘recipient
cell’). The particle’s perinuclear localization in the donor cells and its movement
associated with the cell migration suggested that the particle is fully internalized by the
donor cell. At the moment of transfer the donor and recipient cells align each other and
their membranes appear to expand and open to accommodate the particles. The
transferred particle appears then to migrate to the perinuclear region of the recipient cell
suggesting fully internalization.

Figure 10 Real-time confocal imaging of HMVECs containing 3.2 µm particles at
37ºC. Transfer of the particle between cells is highlighted by pseudo-coloring the cells:
blue the donor cell and red the recipient cell (Top). TEM images of HMVECs incubated
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for four hours with 3.2 µm particles. Scale bars are respectively 10 µm, 2 µm and
500nm (Bottom).
TEM micrographs of HMVECs treated for 4 hours with silicon particles (Figure
10 C) show images of adjacent cells containing particles which would support the direct
transfer between cells. The particles are indeed near the cells membrane boundaries,
where the two membranes appear fused each other suggesting fusion of the two cells. In
The TEM images we also observed particles in the area surrounding the cells enclosed
in membranes (Figure 10 D), which could potentially be particles secreted by the cells.
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Figure 11 Confocal images (Top) of HMVECs incubated with 3.2 µm particles at 37ºC
(5:1 particles/ cells). Cells were stained with Alexa Fluor 555 Phalloidin while the
particles are fluorescently labeled. Pseudo-colored SEM images (middle) of HMVECs
interacting with 3.2 µm porous silicon particles. TEM micrographs (bottom) of
HMVECs incubated with 3.2 µm particles at 37ºC for 4 hours. Pseudopodia containing
particles are visible in both SEM and TEM images. (scale bar 10µm and 2µm
respectively)
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In addition Figure 11 top (Data generated by Dr. Rita Serda) shows confocal
images of Alexa fluor Phalloidin stained HMVECs where pseudopodia connecting the
cells presenting actin filaments is visible. Similarly elongated cellular structures
connecting neighbor cells that also contain silicon particles are visible in SEM (Data
generated by Dr. Rita Serda) and TEM images (Figure 11, middle and bottom). These
types of pseudopodia are very close in structure to the tunneling-nanotubes (TNTs)
which are thin tubular membrane protrusions known to be involved in communication
65

, transfer of organelles and long distance connectivity between cells
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. TNTs have

been shown to be exploited by cells for the intercellular transport of nanoparticles. Mi et
al.67 followed the fate of quantum dots micron-aggregates in human hepatocellular
carcinoma cells and observed transfer between cells happening through the formation of
TNTs, which connected the two cells involved in the process. The particles transported
along the TNTs were encapsulated in lysosomes and the whole organelle was
transferred between the cells.
Although these results cannot fully explain the transfer mechanism, they can
qualitatively describe the process, highlighting the complexity and dynamicity of the
interaction of cells with particles.
Moreover Figure 12 reports another time-lapse sequence of confocal images
acquired in the same experiment, but in a separate field of view. The images show the
transfer of two particles between 2 adjacent cells (pseudo colored in pink and blue)
mediated by a small active cell (green cell), which acts as a shuttle. This ‘shuttle cell’
transfers the first particles (Figure 12A) and then goes back to the donor cells (Figure
12B) and picks up another particle. From the sequential images it is possible to see how
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the donor cells is extended in the region where the transfer occurs and how the green
cell
ell precisely attached to that location and grab the particle.

Figure 12 Real-time
time confocal imaging of HMVECs containing 3.2 µm
µ particles
undergoing intercellular transfer. The cell
cells have been pseudo colored to highlight the
cellular margins and the white harrow points to the particle involved into the process.

The rate of inter-cellular
cellular transfer was also quantified by means of Imagestreaming X
System and Ideas software, in collabora
collaboration with Dr.Summers
Summers and Dr. Rees at the
University of Swansea, in UK. Two populations of cells, respectively containing red
(Alexa Fluor 555) or green (Alexa Fluor 488)
488)-labelled
labelled microparticles, were co-cultured
co
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for 24 hours and dual labeled cells were qua
quantified with the system (Figure 13).
1 The
single labeled populations were used as controls to set up the spectral compensation.
When the cells were co-cultured
cultured in regular mediun containing serum the exchange after
24 hours was 1% while when the cells were cultured in serum
serum-free
free media the exchange
increased to 5%. This indicates an involvement of serum in the process and the
possibility to manipulate the extent of the process.

Figure 13 Estimation of silicon microparticle exchange between HMVEC.
HMVEC HMVEC
were treated with single-label
label microparticles (green or red) for 24 hr followed by coculture for an additional 24 hr. Imagestream X flow cytometer and Ideas software were
used to image cells and estimate dual-labeled cells. The extent of the exchange of
microparticle between
een HMVEC in the presence and absence of serum was also
assessed.

This novel phenomenon brings up questions regarding the possibility of
achieving long distance communication between cells with transfer of particles.
p
It
appears that multiple different mechanisms such as ddirect
irect cell transfer, TNTs and cell
43

shuttling could potentially be involved in the transfer of micro-particles between cells
bringing additional level of complexity to intra and inter cellular trafficking of particles.
In addition the increase in the rate of exchange during serum-starvation may suggest
that environmental stress might stimulate the exchange. This could be potentially
exploited in tumor environment to rapidly distribute the particles and their payloads
between cancer cells.

3.2 Multistage Vectors
3.2.1 Assembly and Characterization

S1MPs were the first components in the assembly of our MSV system serving as
carriers for S2NP that can be loaded into the porous structure. The loading procedure
was based on capillary suction of the solution containing the S2NP into the pores of the
S1MP. The entrapment and retention of the second stage depends on pore size and the
electrostatic interactions between the nanoparticles and the porous silicon surface. Both
of these parameters can be tuned to achieve the optimal condition for a given S2NP.
This allows our system to be very versatile in terms of payloads possibilities.
In order to study the impact of the MSV systems and its intracellular traffic in
endothelial cells, we assembled the system loading S1MPs with SPIOs. SPIOs can be
used as magnetic resonance imaging (MRI) contrasts agents given their ability to
decrease the relation time, T2, when accumulating in a region. They are also employed
as hyperthermia agents, targeted drug delivery and cell separation. SPIOs are
commercially available in many sizes ranging from a few to hundreds of nanometers in
diameter with several different surface coatings such as synthetic polymers and
polysaccharides

17

. For the study we employed 15 nm SPIOs coated with amino-

polyethylene glycol (PEG) polymer (NH2-PEG SPIOs), since from previous studies

68
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they resulted the best choice in terms of loading capacity into our MSV. The
physicochemical characteristics of the nanoparticles were verified employing Zeta
Potential analysis and Fourier Transform Infrared (FTIR) - spectroscopy. The particles
charge, measured through zeta potential, was checked for NH2-PEG SPIOs and
oxidized silicon particles both in phosphate buffer (pH7) and borate buffer (pH5). The
NH2-PEG SPIOs net charge were -4mV and +31.2 mV respectively in phosphate (PBS)
and borate buffer while oxidized porous silicon particles were respectively -22.5mV and
-28mV, showing complementary electrostatic conditions between the two components
of our system especially in borate buffer, which was therefore chosen as loading
solution for multistage particle assembly. The stability of the SPIOs’ coating was tested
by incubating the particles for 6 days in PBS (pH 7) and regularly testing the zeta
potential in order to confirm the constant value of surface charge of the particles
throughout the experiment.
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Figure 14 TEM micrographs of 3.2
3.2µm
m porous silicon particles loaded with
15nm iron oxide nanoparticles (TOP image). FTIR spectra of carboxylated
(COO-IO) and amino-PEG
PEG (NH2
(NH2-PEG-IO)
IO) iron oxide nanoparticles (bottom
image) (Ferrati
Ferrati et al. ‘Intracellular trafficking ooff silicon particles and logiclogic
embedded vectors’ Nanoscale 2010, Courtesy of RSCPublishing).

FTIR spectroscopy was performed on NH2-PEG SPIOs and compared to
carboxylated SPIOs (Figure
Figure 14, bottom). NH2-PEG SPIOs spectrum highlighted
highlight the
presence of the characteristic peaks for primary amines at 3341 cm-1 (NH) and 1298
cm-1 (CN) and the CH stretching at 2922 -2853 cm-1 in addition to the PEG bands
presented on both types of particles such as the bands at 1700 cm-1 (COOH) and 1104
cm-1 (CH2-OH).
The NH2-PEG SPIOs were loaded through capillary action into 3.2 µm mesopourous
discoidal silicon particles and the amount lloaded was evaluated by induced coupled
plasma optical emission spectroscopy (ICP
(ICP-OES) resulting in 6.4µg
g of iron per 3 x 106
silicon particles ( 21% loading efficiency). TEM images, in Figure 14 top, show silicon
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particles loaded with the amino-PEG SPIOs, with a detailed zoom on the pores of the
particles.
3.2.2 Intracellular Traffic of MSV

The intracellular trafficking of the MSV was studied in HMVECs cells
employing TEM microscopy. At early time points (24 and 32 hours) it was possible to
image the assembled system internalized in phagosomes into the cells. The SPIOs were
still predominantly associated with the carriers although in some phagosomes, regions
rich in nanoparticles started to dissociate creating separated vesicles containing SPIOs.
In Figure 15 the sequence of events is recapitulated with particular focus on a
membrane protrusion budding from the original endosome which will then form a
unique vesicle free to independently traffic in the cytoplasm. This suggests an active
sorting of the SPIOs from the carriers over time.
We were also interested in understanding the long term fate of the S2NPs.
Phenomenon of exocytosis of nanoparticles such as PLGA nanoparticles, carbon
nanotubes or SPIOs have been reported in literature.

Figure 15 TEM micrographs of multistage system after up take by HMVECs. The
system was assembled loading porous silicon microparticles with 15nm amino-PEG
SPIOs. Sorting of SPIOs in unique vesicles presenting characteristics of
multivesicular bodies is visible overtime (Ferrati et al. ‘Intracellular trafficking of
silicon particles and logic-embedded vectors’ Nanoscale 2010, Courtesy of
RSCPublishing).
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To evaluate possible exocytosis of our nanoparticles from HMVECs, we
quantitatively measured the concentration of iron over time in the supernatant of cells
incubated with the MSV employing ICP-OES. The data in Figure 16 B is reported as
percentage of iron released with respect to the SPIOs effectively delivered. The latter
was calculated evaluating the initial amount of iron delivered to the cells and
subtracting the amount of free particles still present in the medium at 12 hours, since
these particles were not internalized and therefore removed during the washing step. We
also normalized the results for the iron presents in untreated cells. The amount of SPIOs
released per day was found to be on average 25%. This result was compared to the
release of free amino-PEG SPIOs not loaded into the multistage system which was on
average lower (around 12%). The difference in secretion could be due to difference in
trafficking and sorting of endosomes as well as a difference in absolute values of iron
per cells which may impact the cellular secretion itself.
TEM images (Figure 16 A) of MSV incubated in HMVEC cells for 7 days
supported the decrease of SPIOs from the primary carrier over time. Together this data
suggests an active release of S2NPs from the pores of the silicon particles with potential
subsequent exocytosis of SPIOs.
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Figure 16 Long term fate of SPIOs loaded into the multistage system. A) TEM
image showing the majority of SPIOs been released after 7 days incubation in
cells. B) Increase of iron concentration in the medium over time after incubation
of multistage (GP-NH) or free SPIOs in HMVECs (Ferrati et al. ‘Intracellular
trafficking of silicon particles and logic-embedded vectors’ Nanoscale 2010,
Courtesy of RSCPublishing).

3.3 Secreted Biovesicles as Mediator for Intercellular Transfer of
Nanoparticles.
The employment of nanoparticles for biomedical applications has brought up
questions about their biodistribution in the body and their fate at a cellular level 69. Our
mitotic trafficking data explained particles redistribution during proliferation while the
transfer of micro-particles between cells and the preliminary results reporting the
increase of iron concentration in the medium over time after treatment of endothelial
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cells with our MSV loaded with second stage SPIOs suggested possible secretion of
both S1MPs as well S2NPs from cells. For S1MPs we saw that multiple mechanisms
were potentially involved into the transfer such as TNTs and direct transfer, we next
decided to further investigate the form and mechanism by which S2NPs were instead
secreted from HMVECs. For simplicity, we employed free SPIOs as nanoparticles and
we characterized their intracellular traffic briefly recapitulating their uptake mechanism
in HMVECs and then focusing on their secretion.

3.3.1 Endocytosis of PEI-SPIOs in HMVECs
TEM micrographs (Figure 17 B-D) of HMVECs cells incubated with PEI-SPIOs
for 6 hours show the uptake of particles by cells and their localization within
endosomes. The encapsulation of the particles in vesicles was also confirmed by
confocal microscopy (Figure 17 A). 488-labeled SPIOs were incubated with 594- Wheat
Germ Agglutinin (WGA) stained cells. WGA selectively binds to N-acetylglucosamine

and N-acetylneuraminic acid thus staining the cellular membrane, which, during the
uptake of the particles, forms the endosomes. The co-localizing of particles within the
vesicles resulted in a yellow coloration of the endosomes as the sum of the two
fluorescent dyes (average overlap coefficient resulted 0.980). Early endosomes are
known to be able to mature into late endosomes (also known as multivesicular bodies),
which can then fuse with either lysosomes or autophagosomes forming respectively a
mature form of lysosomes or hybrid structures such as amphisomes and autolysosomes.
Both mature lysosomes and hybrid structures can retain markers of the original
organelles, such as: Rab7, LC3 and Lamp1, which are markers for late endosomes,
autophagosomes and lysosomes respectively. Therefore any of the markers can be used
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to label these organelles. The maturation and fusion between organelles is associated
with a movement toward the perinuclear region. From TEM and confocal images, the
presence of SPIOs within the endosomes does not seem to affect their maturation and
their final co-localization in the perinuclear region.
Moreover, the internalization of the particles did not negatively impact the cells
as both their morphology and subcellular structure, such as nuclei and organelles;
appear healthy in the TEM micrographs. In addition, the MTT assay (Figure 18 A)
confirmed that the cellular proliferation over 4 days of incubation with PEI-SPIOs (2
µg/ml) was not affected.

Figure 17 A) Co-localization of 488 Dylight labeled-PEI-SPIOs with 594-WGAlabeled vesicles after overnight incubation in HMVECs. B) TEM micrographs of
HMVECs incubated with PEI-SPIOs. Vesicles containing SPIOs are visible inside as
well as outside the cell.

3.3.2 Secretion of Microvesicles Containing SPIOs

In our previous set of experiments we hypothesized that the increase of iron
concentration in the supernatant was due to the exocytosis of second stage
nanoparticles, released from the silicon carrier. In the present study we further
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investigated this phenomenon to understand in which form the SPIOs were secreted.
The TEM micrograph reported in Figures 17-C, clearly shows that endocytosed-SPIOs
can be secreted into the surrounding area by HMVECs encapsulated into biovesicles.
Next we analyzed the content of the conditional medium of HMVECs recovered after
three days of incubation with PEI-SPIOs. We concentrated the supernatant by
centrifugation obtaining a dark pellet (Figure 18 B), which suggested the presence of
secreted iron nanoparticles.

A

B

Figure 18 A) MTT proliferation assay of HMVECs incubated with
PEI-SPIOs. B) Concentrated conditional medium form HMVECs
incubated for 3 days with PEI-SPOIs.

The ultrastructural characterization of the samples by TEM revealed the
presence of vesicles containing nanoparticles (Figure 19). The vesicles have an average
size of 1µm and from a morphological point of view they present various characteristics
of multivesicular bodies (MVB) (Figure 19 A), autophagosomes (Figure 19 C) and
primary lysosomes (Figure 19 B) containing recycled membrane bundles, smaller
endocytic vesicles, partially degraded ribosomes and rough ER. Next we tested the
presence of Lamp1 as a membrane biomarker for the biovesicles.
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B

C

Figure 19 TEM micrographs of concentrated medium form HMVECs incubated with
PEI-SPIOs. The ultra-structural analysis revealed presence of secreted microvesicles
containing SPIOs.( Scale bar 100 nm)

The concentrated pellet was incubated with a FITC labeled Lamp1 antibody and
analyzed with confocal microscopy, using reflectance to visualize the clusters of iron
oxide nanoparticles. Biovesicles containing iron nanoparticles appeared to be Lamp1
positive as shown in Figure 21-A, confirming their endosomal origin. In addition it was
previously reported that exocytosis depends on the molecular weight of the cargo: lower
molecular weight molecules are recycled from early endosomes while higher molecular
weight molecules are secreted from larger and slower compartments, presumably
lysosomes 70. Exocytosis of fluid phase markers was therefore faster than the secretion
of nanoparticles due to the different size and nature of the cargo
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. The release of

SPIOs appears to be slow and it becomes substantial after 48 hours suggesting release
from the slower compartment.
We have schematically outlined in Figure 20 a possible mechanism for the
release of vesicle-enclosed nanoparticles from endothelial cells. The first part of the
schematic summarizes the well-established cellular uptake of nanoparticles through
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endocytosis, while the second part describes the rerouting of mature endocytic vesiclescontaining nanoparticles and their release outside the cell.

Figure 20 Schematic of proposed mechanism of secretion of microvesicles
containing nanoparticles. The SPIOs enter in the cells via endocytosis trafficking and
therefore they traffic to early endosomes (1). From there, the vesicles containing
SPIOs mature in late endosomes or multivesicular bodies (MVB) (2) and then finally
fuse to either lysosomes (3) or auotphagosomes (4) to create respectively lysosomes
and autolysosomes. These matured vesicles could then be secreted outside the cell as
whole structures (6).
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This hypothesis is supported by previous knowledge of similar mechanisms in
endothelial cells. These cells are naturally programmed to control the passage of fluids
and molecules through vessel walls and one of the mechanisms they exploit is
transcytosis. During this process they internalize cargos from the lumen side and
subsequently release it in the interstitial space; an example is the GP60 receptormediated transcellular transport of albumin across the endothelium
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. Therefore

vascular cells present the machinery to perform exocytosis. Vascular endothelial growth
factor (VEGF)-activated endothelial cells
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have also recently been shown to release

specialized granules, called Weibed-Palade bodies (WPb), which are up to 3 µm in
length and 0.1-0.2 µm in width 73, comparable with our vesicle size.
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Figure 21 A) Confocal images of FITC
FITC-Lamp1
Lamp1 labeled secreted vesicles,
SPIOs are visualized in reflectance. B) Confocal images of FITC--Lamp1
labeled secreted vesicles incubated 224
4 hours with 4T1 cancer cells. 4T1
4
are
visualized in bright field and th
their nuclei are stained with DAPI.
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3.3.3 Intercellular Transfer of Nanoparticles through Microvesicles.

In order to test if endothelial cell derived microvesicles could be involved in the
inter-cellular transfer of nanoparticles, Lamp1-FITC labeled microvesicles were
incubated with 4T1 breast cancer cells for 24 hours. Confocal microscopy of the treated
cells (Figure 21, B-C) revealed an association of the FITC-vesicles with the cancer
cells. The presence of SPIOs clusters within the green vesicles was detected by
reflectance while the cell morphology was assessed by staining the nuclei with DAPI
and visualizing the cell borders with bright field. To confirm microvesicle uptake by
recipient cells we also performed TEM imaging on three different cell lines incubated
overnight with the concentrated pellet secreted by endothelial cells (Figure 22).
HMVECs (Figure 22-A) cells as well as two breast cancer cell lines, MCF7 and 4T1
(respectively Figure 22 B and C), were employed for the experiment. From the TEM
micrographs we can clearly see the presence of iron oxide nanoparticles confined in
vesicles within the recipient cells.
Together the confocal and TEM data suggest the uptake of the cell-released
microvesicles containing SPIOs by recipient cells and therefore their possible role as a
mediator of nanoparticles transport between different cells. The process is complex and
dynamic as the vesicles can be re-internalized by other endothelial cells or by different
types of cells, such as cancer cells. Similar results were obtained by Luciani et al.
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,

although their study was limited to macrophages as donor and recipient cells. Our data
therefore extends the study to a wider range of cells suggesting a more ubiquitous
presence of this process. Given their bio-genesis, the use of these microvesicles as
carriers for nanoparticles would provide additional advantages in term of compatibility,
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cellular uptake and trafficking, as compared to synthetic biovesicles, such as
magnetoliposomes, which have already shown to enhance the contrast agent properties
of SPIOs due to their confinement 74.
From a broader point of view, since the vasculature represents a biological
barrier in vivo for i.v. injected drug carriers, which has to be overcome in order to reach
the lesion site
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, we therefore propose that the biological vesicles could be

exploited to allow nanoparticles to cross the endothelial barrier and transfer particles
and drugs to tumor cells. Although further studies are necessary to fully characterize the
pathway, we can speculate that in the tumor environment, where VEGF concentration is
high, secretion of biovesicles could be potentially more prevalent, as shown for WPb,
leading to substantial release of microvesicles containing S2NPs.
This finding expands our previous data reporting evidence of exocytosis of
nanoparticles from HMVECs upon treatment with a MSVs loaded with amino-PEG
SPIOs
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. The hypothesized mechanism of secretion could give insights into the long

term fate of the unique vesicles that were budding overtime from the endosome
encapsulating the silicon carrier. The novel vesicles were shown to independently traffic
in the cells and they could potentially be secreted as a whole structure explaining the
increase of iron in the supernatant.
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Figure 22 TEM micrographs of recipient cells. A) HMVECs B) MCF7 C) 4T1
incubated overnight with secreted microvesicles. In each line represent consecutive
zooms highlighting the presence of iron oxide nanoparticles in the up taken vesicles.
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4 Conclusions
In summary, in this work we investigated the cellular trafficking of our
multistage drug delivery system, assembled by loading porous silicon microparticles
with super-paramagnetic iron oxide nanoparticles, in endothelial cells.
The first part of the study was focused on the understanding of the intracellular
localization and migration properties of the silicon carriers. We demonstrate that the
regardless the size (1.6 or 3.2 µm) or the surface functionalization (APTES vs oxidized)
the silicon carriers are internalized by endothelial cells through phagocytosis and end up
in the cells encapsulated in vesicles (phagosomes). These phagosomes are able to
mature and move toward the perinuclear region through an active-microtubule-mediated
mechanism. The rate of migration for different variations of microparticles was
characterized and no impact on the microparticle size, charge and shape was observed.
We also studied the long-termfate of the particles with respect to cell proliferation and
intercellular transfer, highlighting particle partitioning between daughter cells as well as
intercellular transfer.
The second part of the study was instead focused on the loading of the
multistage system with second stage nanoparticles (SPIOs) and investigating the
intracellular fate of the SPIOs once the MSVs were internalized in HMVECs. As
expected, once internalized in the cells, MSVs were encapsulated in phagosomes, but
the SPIOs were released over time from the pores and were sorted into unique vesicles
(most likely multi-vesicular bodies) which were able to independently traffic inside the
cells. Quantitative increase of iron over time in the supernatant suggested the possibility
of iron oxide exocytosis.
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This hypothesis was further investigated in the third and last part of the work
where, through ultra-structural analysis of the conditional medium of HMVECs
incubated with SPIOs, it was possible to identify endothelial-cell secreted biovesicles
containing iron oxide nanoparticles. The morphology and dimension suggest that these
microvesicles are lysosomal in origin with combined features of multivesicular bodies
and autophagosomes. This result supports the possibility of a more ubiquitous presence
of the release of microvesicles among cells which are not part of the phagocytic
immunosystem and provides further insights into the long term fate of nanoparticles in
cells. These microvesicles can also mediate the transfer of SPIOs between cells, not
only between endothelial cells but also between cancer cells, we therefore propose that
the biological event of intercellular transfer of nanoparticles within vesicles could be
exploited to allow nanoparticles to cross the endothelial barrier and provide signals or
therapeutics to tumor cells.

61

5 Bibliography

1.

Theis, T.; Parr, D.; Binks, P.; Ying, J.; Drexler, K. E.; Schepers, E.; Mullis, K.;

Bai, C.; Boland, J. J.; Langer, R.; Dobson, P.; Rao, C. N.; Ferrari, M.,
nan'o.tech.nol'o.gy n. Nat Nanotechnol 2006, 1 (1), 8-10.
2.

(a) Blanco, E.; Hsiao, A.; Mann, A. P.; Landry, M. G.; Meric-Bernstam, F.;

Ferrari, M., Nanomedicine in cancer therapy: innovative trends and prospects. Cancer
Sci 2011, 102 (7), 1247-52; (b) Bharali, D. J.; Khalil, M.; Gurbuz, M.; Simone, T. M.;
Mousa, S. A., Nanoparticles and cancer therapy: a concise review with emphasis on
dendrimers. Int J Nanomedicine 2009, 4, 1-7; (c) Ferrari, M., Cancer nanotechnology:
opportunities and challenges. Nat Rev Cancer 2005, 5 (3), 161-71.
3.

Liu, Y.; Miyoshi, H.; Nakamura, M., Nanomedicine for drug delivery and

imaging: a promising avenue for cancer therapy and diagnosis using targeted functional
nanoparticles. Int J Cancer 2007, 120 (12), 2527-37.
4.

Seigneuric, R.; Markey, L.; Nuyten, D. S.; Dubernet, C.; Evelo, C. T.; Finot, E.;

Garrido, C., From nanotechnology to nanomedicine: applications to cancer research.
Curr Mol Med 2010, 10 (7), 640-52.
5.

(a) Choi, H. S.; Liu, W.; Liu, F.; Nasr, K.; Misra, P.; Bawendi, M. G.; Frangioni,

J. V., Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol 2010,
5 (1), 42-7; (b) Farokhzad, O. C.; Cheng, J.; Teply, B. A.; Sherifi, I.; Jon, S.; Kantoff, P.
W.; Richie, J. P.; Langer, R., Targeted nanoparticle-aptamer bioconjugates for cancer
chemotherapy in vivo. Proc Natl Acad Sci U S A 2006, 103 (16), 6315-20.

62

6.

Ding, B. S.; Dziubla, T.; Shuvaev, V. V.; Muro, S.; Muzykantov, V. R.,

Advanced drug delivery systems that target the vascular endothelium. Mol Interv 2006,
6 (2), 98-112.
7.

Anton, K.; Glod, J., Targeting the tumor stroma in cancer therapy. Curr Pharm

Biotechnol 2009, 10 (2), 185-91.
8.

Hilgenbrink, A. R.; Low, P. S., Folate receptor-mediated drug targeting: from

therapeutics to diagnostics. J Pharm Sci 2005, 94 (10), 2135-46.
9.

(a) Sugahara, K. N.; Teesalu, T.; Karmali, P. P.; Kotamraju, V. R.; Agemy, L.;

Greenwald, D. R.; Ruoslahti, E., Coadministration of a tumor-penetrating peptide
enhances the efficacy of cancer drugs. Science 2010, 328 (5981), 1031-5; (b) Ruoslahti,
E.; Bhatia, S. N.; Sailor, M. J., Targeting of drugs and nanoparticles to tumors. J Cell
Biol 2010, 188 (6), 759-68.
10.

Gabizon, A. A., Pegylated liposomal doxorubicin: metamorphosis of an old drug

into a new form of chemotherapy. Cancer Invest 2001, 19 (4), 424-36.
11.

Desai, N.; Trieu, V.; Yao, Z.; Louie, L.; Ci, S.; Yang, A.; Tao, C.; De, T.; Beals,

B.; Dykes, D.; Noker, P.; Yao, R.; Labao, E.; Hawkins, M.; Soon-Shiong, P., Increased
antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of
cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based
paclitaxel. Clin Cancer Res 2006, 12 (4), 1317-24.
12.

Harris, T. J.; Green, J. J.; Fung, P. W.; Langer, R.; Anderson, D. G.; Bhatia, S.

N., Tissue-specific gene delivery via nanoparticle coating. Biomaterials 2010, 31 (5),
998-1006.

63

13.

Li, S. D.; Chen, Y. C.; Hackett, M. J.; Huang, L., Tumor-targeted delivery of

siRNA by self-assembled nanoparticles. Mol Ther 2008, 16 (1), 163-9.
14.

Patil, Y.; Panyam, J., Polymeric nanoparticles for siRNA delivery and gene

silencing. Int J Pharm 2009, 367 (1-2), 195-203.
15.

Davis, M. E.; Zuckerman, J. E.; Choi, C. H.; Seligson, D.; Tolcher, A.; Alabi, C.

A.; Yen, Y.; Heidel, J. D.; Ribas, A., Evidence of RNAi in humans from systemically
administered siRNA via targeted nanoparticles. Nature 2010, 464 (7291), 1067-70.
16.

Pinaud, F.; Michalet, X.; Bentolila, L. A.; Tsay, J. M.; Doose, S.; Li, J. J.; Iyer,

G.; Weiss, S., Advances in fluorescence imaging with quantum dot bio-probes.
Biomaterials 2006, 27 (9), 1679-87.
17.

Tong, S.; Hou, S.; Zheng, Z.; Zhou, J.; Bao, G., Coating optimization of

superparamagnetic iron oxide nanoparticles for high T2 relaxivity. Nano Lett 2010, 10
(11), 4607-13.
18.

Jain, T. K.; Reddy, M. K.; Morales, M. A.; Leslie-Pelecky, D. L.; Labhasetwar,

V., Biodistribution, clearance, and biocompatibility of iron oxide magnetic
nanoparticles in rats. Mol Pharm 2008, 5 (2), 316-27.
19.

Thorek, D. L.; Chen, A. K.; Czupryna, J.; Tsourkas, A., Superparamagnetic iron

oxide nanoparticle probes for molecular imaging. Ann Biomed Eng 2006, 34 (1), 23-38.
20.

(a) Au, J. L.; Jang, S. H.; Zheng, J.; Chen, C. T.; Song, S.; Hu, L.; Wientjes, M.

G., Determinants of drug delivery and transport to solid tumors. J Control Release
2001, 74 (1-3), 31-46; (b) Ferrari, M., Frontiers in cancer nanomedicine: directing mass
transport through biological barriers. Trends Biotechnol 2010, 28 (4), 181-188.

64

21.

Nie, S., Understanding and overcoming major barriers in cancer nanomedicine.

Nanomedicine (Lond) 2010, 5 (4), 523-8.
22.

(a) Mehta, D.; Malik, A. B., Signaling mechanisms regulating endothelial

permeability. Physiol Rev 2006, 86 (1), 279-367; (b) Michel, C. C.; Curry, F. E.,
Microvascular permeability. Physiol Rev 1999, 79 (3), 703-61.
23.

Corada, M.; Mariotti, M.; Thurston, G.; Smith, K.; Kunkel, R.; Brockhaus, M.;

Lampugnani, M. G.; Martin-Padura, I.; Stoppacciaro, A.; Ruco, L.; McDonald, D. M.;
Ward, P. A.; Dejana, E., Vascular endothelial-cadherin is an important determinant of
microvascular integrity in vivo. Proc Natl Acad Sci U S A 1999, 96 (17), 9815-20.
24.

Brightman, M. W.; Reese, T. S., Junctions between intimately apposed cell

membranes in the vertebrate brain. J Cell Biol 1969, 40 (3), 648-77; (b) Reese, T. S.;
Karnovsky, M. J., Fine structural localization of a blood-brain barrier to exogenous
peroxidase. J Cell Biol 1967, 34 (1), 207-17.
25.

Takakura, Y.; Mahato, R. I.; Hashida, M., Extravasation of macromolecules.

Adv Drug Deliv Rev 1998, 34 (1), 93-108.
26.

Di Paolo, A.; Bocci, G., Drug distribution in tumors: mechanisms, role in drug

resistance, and methods for modification. Curr Oncol Rep 2007, 9 (2), 109-14.
27.

(a) Minchinton, A. I.; Tannock, I. F., Drug penetration in solid tumours. Nat Rev

Cancer 2006, 6 (8), 583-92; (b) Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K.,
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a
review. J Control Release 2000, 65 (1-2), 271-84; (c) Cairns, R.; Papandreou, I.;
Denko, N., Overcoming physiologic barriers to cancer treatment by molecularly
targeting the tumor microenvironment. Mol Cancer Res 2006, 4 (2), 61-70.

65

28.

(a) Hobbs, S. K.; Monsky, W. L.; Yuan, F.; Roberts, W. G.; Griffith, L.;

Torchilin, V. P.; Jain, R. K., Regulation of transport pathways in tumor vessels: role of
tumor type and microenvironment. Proc Natl Acad Sci U S A 1998, 95 (8), 4607-12; (b)
Iyer, A. K.; Khaled, G.; Fang, J.; Maeda, H., Exploiting the enhanced permeability and
retention effect for tumor targeting. Drug Discov Today 2006, 11 (17-18), 812-8; (c)
Batist, G.; Ramakrishnan, G.; Rao, C. S.; Chandrasekharan, A.; Gutheil, J.; Guthrie, T.;
Shah, P.; Khojasteh, A.; Nair, M. K.; Hoelzer, K.; Tkaczuk, K.; Park, Y. C.; Lee, L. W.,
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated
doxorubicin and cyclophosphamide compared with conventional doxorubicin and
cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin
Oncol 2001, 19 (5), 1444-54.
29.

Wang, Z.; Tiruppathi, C.; Cho, J.; Minshall, R. D.; Malik, A. B., Delivery of

nanoparticle: complexed drugs across the vascular endothelial barrier via caveolae.
IUBMB Life 2011, 63 (8), 659-67.
30.

(a) Chen, K.; Chen, X., Integrin targeted delivery of chemotherapeutics.

Theranostics 2011, 1, 189-200; (b) Xiong, X. B.; Mahmud, A.; Uludag, H.; Lavasanifar,
A., Multifunctional polymeric micelles for enhanced intracellular delivery of
doxorubicin to metastatic cancer cells. Pharm Res 2008, 25 (11), 2555-66.
31.

Tannock, I. F.; Lee, C. M.; Tunggal, J. K.; Cowan, D. S.; Egorin, M. J., Limited

penetration of anticancer drugs through tumor tissue: a potential cause of resistance of
solid tumors to chemotherapy. Clin Cancer Res 2002, 8 (3), 878-84.

66

32.

Netti, P. A.; Berk, D. A.; Swartz, M. A.; Grodzinsky, A. J.; Jain, R. K., Role of

extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000,
60 (9), 2497-503.
33.

Jain, R. K., Transport of molecules across tumor vasculature. Cancer Metastasis

Rev 1987, 6 (4), 559-93.
34.

Ribatti, D.; Mangialardi, G.; Vacca, A., Stephen Paget and the 'seed and soil'

theory of metastatic dissemination. Clin Exp Med 2006, 6 (4), 145-9.
35.

Pollard, J. W., Tumour-educated macrophages promote tumour progression and

metastasis. Nat Rev Cancer 2004, 4 (1), 71-8.
36.

Masamune, A.; Kikuta, K.; Watanabe, T.; Satoh, K.; Hirota, M.; Shimosegawa,

T., Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in
pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2008, 295 (4), G709-17.
37.

Ferrara, N.; Kerbel, R. S., Angiogenesis as a therapeutic target. Nature 2005,

438 (7070), 967-74.
38.

(a) Biswas, S.; Criswell, T. L.; Wang, S. E.; Arteaga, C. L., Inhibition of

transforming growth factor-beta signaling in human cancer: targeting a tumor
suppressor network as a therapeutic strategy. Clin Cancer Res 2006, 12 (14 Pt 1), 41426; (b) Arteaga, C. L.; Hurd, S. D.; Winnier, A. R.; Johnson, M. D.; Fendly, B. M.;
Forbes, J. T., Anti-transforming growth factor (TGF)-beta antibodies inhibit breast
cancer cell tumorigenicity and increase mouse spleen natural killer cell activity.
Implications for a possible role of tumor cell/host TGF-beta interactions in human
breast cancer progression. J Clin Invest 1993, 92 (6), 2569-76; (c) Peng, S. B.; Yan, L.;
Xia, X.; Watkins, S. A.; Brooks, H. B.; Beight, D.; Herron, D. K.; Jones, M. L.; Lampe,

67

J. W.; McMillen, W. T.; Mort, N.; Sawyer, J. S.; Yingling, J. M., Kinetic
characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their
blockade of the epithelial-mesenchymal transition. Biochemistry 2005, 44 (7), 2293304.
39.

Petros, R. A.; DeSimone, J. M., Strategies in the design of nanoparticles for

therapeutic applications. Nat Rev Drug Discov 2010, 9 (8), 615-27.
40.

Rejman, J.; Oberle, V.; Zuhorn, I. S.; Hoekstra, D., Size-dependent

internalization of particles via the pathways of clathrin- and caveolae-mediated
endocytosis. Biochem J 2004, 377 (Pt 1), 159-69.
41.

Bareford, L. M.; Swaan, P. W., Endocytic mechanisms for targeted drug

delivery. Adv Drug Deliv Rev 2007, 59 (8), 748-58.
42.

Mitragotri, S., In drug delivery, shape does matter. Pharm Res 2009, 26 (1),

232-4.
43.

Decuzzi, P.; Ferrari, M., Design maps for nanoparticles targeting the diseased

microvasculature. Biomaterials 2008, 29 (3), 377-84.
44.

Pasqualini, R.; Ruoslahti, E., Organ targeting in vivo using phage display

peptide libraries. Nature 1996, 380 (6572), 364-6.
45.

Kakar, S. S.; Jin, H.; Hong, B.; Eaton, J. W.; Kang, K. A., LHRH receptor

targeted therapy for breast cancer. Adv Exp Med Biol 2008, 614, 285-96.
46.

Olson, W. C.; Heston, W. D.; Rajasekaran, A. K., Clinical trials of cancer

therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials 2007, 2
(3), 182-90.

68

47.

Kularatne, S. A.; Wang, K.; Santhapuram, H. K.; Low, P. S., Prostate-specific

membrane antigen targeted imaging and therapy of prostate cancer using a PSMA
inhibitor as a homing ligand. Mol Pharm 2009, 6 (3), 780-9.
48.

Dharap, S. S.; Wang, Y.; Chandna, P.; Khandare, J. J.; Qiu, B.; Gunaseelan, S.;

Sinko, P. J.; Stein, S.; Farmanfarmaian, A.; Minko, T., Tumor-specific targeting of an
anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A 2005, 102
(36), 12962-7.
49.

Dhar, S.; Gu, F. X.; Langer, R.; Farokhzad, O. C.; Lippard, S. J., Targeted

delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrugPLGA-PEG nanoparticles. Proc Natl Acad Sci U S A 2008, 105 (45), 17356-61.
50.

Gruenberg, J., The endocytic pathway: a mosaic of domains. Nat Rev Mol Cell

Biol 2001, 2 (10), 721-30.
51.

Thery, C.; Zitvogel, L.; Amigorena, S., Exosomes: composition, biogenesis and

function. Nat Rev Immunol 2002, 2 (8), 569-79.
52.

Beyer, C.; Pisetsky, D. S., The role of microparticles in the pathogenesis of

rheumatic diseases. Nat Rev Rheumatol 2010, 6 (1), 21-9.
53.

Panyam, J.; Labhasetwar, V., Dynamics of endocytosis and exocytosis of

poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm
Res 2003, 20 (2), 212-20.
54.

(a) Serda, R. E.; Mack, A.; van de Ven, A. L.; Ferrati, S.; Dunner, K., Jr.; Godin,

B.; Chiappini, C.; Landry, M.; Brousseau, L.; Liu, X.; Bean, A. J.; Ferrari, M., Logicembedded vectors for intracellular partitioning, endosomal escape, and exocytosis of
nanoparticles. Small 2010, 6 (23), 2691-700; (b) Kustermann, E.; Himmelreich, U.;

69

Kandal, K.; Geelen, T.; Ketkar, A.; Wiedermann, D.; Strecker, C.; Esser, J.; Arnhold,
S.; Hoehn, M., Efficient stem cell labeling for MRI studies. Contrast Media Mol
Imaging 2008, 3 (1), 27-37; (c) Luciani, N.; Wilhelm, C.; Gazeau, F., The role of cellreleased microvesicles in the intercellular transfer of magnetic nanoparticles in the
monocyte/macrophage system. Biomaterials 2010, 31 (27), 7061-9.
55.

Jin, H.; Heller, D. A.; Strano, M. S., Single-particle tracking of endocytosis and

exocytosis of single-walled carbon nanotubes in NIH-3T3 cells. Nano Lett 2008, 8 (6),
1577-85.
56.

Wilhelm, C.; Lavialle, F.; Pechoux, C.; Tatischeff, I.; Gazeau, F., Intracellular

trafficking of magnetic nanoparticles to design multifunctional biovesicles. Small 2008,
4 (5), 577-82.
57.

Tasciotti, E.; Liu, X.; Bhavane, R.; Plant, K.; Leonard, A. D.; Price, B. K.;

Cheng, M. M.; Decuzzi, P.; Tour, J. M.; Robertson, F.; Ferrari, M., Mesoporous silicon
particles as a multistage delivery system for imaging and therapeutic applications. Nat
Nanotechnol 2008, 3 (3), 151-7.
58.

(a) Godin, B.; Tasciotti, E.; Liu, X.; Serda, R. E.; Ferrari, M., Multistage

nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem
Res 2011, 44 (10), 979-89; (b) Serda, R. E.; Godin, B.; Blanco, E.; Chiappini, C.;
Ferrari, M., Multi-stage delivery nano-particle systems for therapeutic applications.
Biochim Biophys Acta 2011, 1810 (3), 317-29.
59.

Decuzzi, P.; Godin, B.; Tanaka, T.; Lee, S. Y.; Chiappini, C.; Liu, X.; Ferrari,

M., Size and shape effects in the biodistribution of intravascularly injected particles. J
Control Release 2010, 141 (3), 320-7.

70

60.

Chiappini, C.; Tasciotti, E.; Fakhoury, J. R.; Fine, D.; Pullan, L.; Wang, Y. C.;

Fu, L.; Liu, X.; Ferrari, M., Tailored porous silicon microparticles: fabrication and
properties. Chemphyschem 2010, 11 (5), 1029-35.
61.

Ciro Chiappini; Ennio Tasciotti; Rita E. Serda; Lou Brousseau; Xuewu Liu;

Ferrari, M., Mesoporous silicon particles as intravascular drug delivery vectors:
fabrication, in-vitro, and in-vivo assessments. physica status solidi 2011, 8 (6), 1826–
1832.
62.

Kolonin, M.; Pasqualini, R.; Arap, W., Molecular addresses in blood vessels as

targets for therapy. Curr Opin Chem Biol 2001, 5 (3), 308-13.
63.

Serda, R. E.; Gu, J.; Bhavane, R. C.; Liu, X.; Chiappini, C.; Decuzzi, P.; Ferrari,

M., The association of silicon microparticles with endothelial cells in drug delivery to
the vasculature. Biomaterials 2009, 30 (13), 2440-8.
64.

Ferrati, S.; Mack, A.; Chiappini, C.; Liu, X.; Bean, A. J.; Ferrari, M.; Serda, R.

E., Intracellular trafficking of silicon particles and logic-embedded vectors. Nanoscale
2010, 2 (8), 1512-20.
65.

Domhan, S.; Ma, L.; Tai, A.; Anaya, Z.; Beheshti, A.; Zeier, M.; Hlatky, L.;

Abdollahi, A., Intercellular communication by exchange of cytoplasmic material via
tunneling nano-tube like structures in primary human renal epithelial cells. PLoS One
2011, 6 (6), e21283.
66.

Gurke, S.; Barroso, J. F.; Gerdes, H. H., The art of cellular communication:

tunneling nanotubes bridge the divide. Histochem Cell Biol 2008, 129 (5), 539-50.

71

67.

Mi, L.; Xiong, R.; Zhang, Y.; Li, Z.; Yang, W.; Chen, J.; Wang, P., Microscopic

Observation of the Intercellular Transport of CdTe Quantum Do. Journal of
Biomaterials and Nanobiotechnology 2011, 2, 173-180.
68.

Serda, R. E.; Mack, A.; Pulikkathara, M.; Zaske, A. M.; Chiappini, C.;

Fakhoury, J. R.; Webb, D.; Godin, B.; Conyers, J. L.; Liu, X. W.; Bankson, J. A.;
Ferrari, M., Cellular association and assembly of a multistage delivery system. Small
2010, 6 (12), 1329-40.
69.

Tanaka, T.; Godin, B.; Bhavane, R.; Nieves-Alicea, R.; Gu, J.; Liu, X.;

Chiappini, C.; Fakhoury, J. R.; Amra, S.; Ewing, A.; Li, Q.; Fidler, I. J.; Ferrari, M., In
vivo evaluation of safety of nanoporous silicon carriers following single and multiple
dose intravenous administrations in mice. Int J Pharm 2010, 402 (1-2), 190-7.
70.

(a) Swanson, J. A.; Yirinec, B. D.; Silverstein, S. C., Phorbol esters and

horseradish peroxidase stimulate pinocytosis and redirect the flow of pinocytosed fluid
in macrophages. J Cell Biol 1985, 100 (3), 851-9; (b) Buckmaster, M. J.; Lo Braico, D.,
Jr.; Ferris, A. L.; Storrie, B., Retention of pinocytized solute by CHO cell lysosomes
correlates with molecular weight. Cell Biol Int Rep 1987, 11 (7), 501-7.
71.

Vogel, S. M.; Minshall, R. D.; Pilipovic, M.; Tiruppathi, C.; Malik, A. B.,

Albumin uptake and transcytosis in endothelial cells in vivo induced by albuminbinding protein. Am J Physiol Lung Cell Mol Physiol 2001, 281 (6), L1512-22.
72.

Matsushita, K.; Yamakuchi, M.; Morrell, C. N.; Ozaki, M.; O'Rourke, B.; Irani,

K.; Lowenstein, C. J., Vascular endothelial growth factor regulation of Weibel-Paladebody exocytosis. Blood 2005, 105 (1), 207-14.

72

73.

(a) Valentijn, K. M.; Sadler, J. E.; Valentijn, J. A.; Voorberg, J.; Eikenboom, J.,

Functional architecture of Weibel-Palade bodies. Blood 2011, 117 (19), 5033-43; (b)
Valentijn, K. M.; van Driel, L. F.; Mourik, M. J.; Hendriks, G. J.; Arends, T. J.; Koster,
A. J.; Valentijn, J. A., Multigranular exocytosis of Weibel-Palade bodies in vascular
endothelial cells. Blood 2010, 116 (10), 1807-16.
74.

Martina, M. S.; Fortin, J. P.; Menager, C.; Clement, O.; Barratt, G.; Grabielle-

Madelmont, C.; Gazeau, F.; Cabuil, V.; Lesieur, S., Generation of superparamagnetic
liposomes revealed as highly efficient MRI contrast agents for in vivo imaging. J Am
Chem Soc 2005, 127 (30), 10676-85.
75.

Jain, R. K.; Stylianopoulos, T., Delivering nanomedicine to solid tumors. Nat

Rev Clin Oncol 2010, 7 (11), 653-64.

73

6 Vita
Silvia Ferrati was born in Florence, Italy on June 22, 1981, the Daughter of
Rossella Gori and Maurizio Ferrati.
After completing her work at A. Gramsci High School, Florence, Italy in 2000,
she entered University of Florence in Florence, Italy. She received the degree of Master
of Science with a major in physical-chemistry from the University of Florence in May,
2006.
She then entered University of Venice (CIVEN program) in Venice, Italy, from
which she received her degree of Master of Science with a major in nanotechnology in
December 2007, after the completion of her internship in the Department of Biomedical
Engineering of The University of Texas Health Science Center at Houston.
In January 2008, she entered The University of Texas Health Science Center at
Houston Graduate School of Biomedical Sciences as a graduate student.

Permanent address:

2120 El Paseo, Apt. #2804
Houston, Texas 77054
USA

74

